PHILADELPHIA, March 7, 2018 /PRNewswire/ -- Aevi
Genomic Medicine, Inc. (NASDAQ MKT: GNMX) today announced that
it has expanded its collaboration with Kyowa Hakko Kirin Co., Ltd.
(Kyowa Hakko Kirin) with the signing of an option agreement for an
early stage monoclonal antibody program ("program") in an
ultra-orphan pediatric indication.
Aevi Genomic Medicine and Kyowa Hakko Kirin have developed a
collaboration framework to advance preclinical programs into the
clinic, leveraging Aevi Genomic Medicine's expertise in rare and
orphan pediatric diseases, and its ongoing collaboration with
Children's Hospital of Philadelphia ("CHOP") and the biobank at the
Center for Applied Genomics at CHOP. This new program will focus on
an undisclosed, first-in-class monoclonal antibody targeting a
specific cell surface marker implicated in an auto-immune
ultra-orphan disease that primarily affects children.
"We are very excited to be deepening our partnership with Kyowa
Hakko Kirin to identify and validate new potential targets in human
disease," said Garry Neil, Chief
Scientific Officer of Aevi Genomic Medicine. "We believe that this
new program will demonstrate an ability to shorten development of
novel medicines through a rigorous precision medicine methodology
that pairs targeted KHK discoveries with the right patients in rare
and orphan diseases by utilizing the comprehensive collection
of rare and orphan specimens in the CHOP Biobank."
Financial and other terms of the deal were not disclosed.
About Aevi Genomic Medicine, Inc.
Aevi Genomic Medicine, Inc. is dedicated to unlocking the
potential of genomic medicine to translate genetic discoveries into
novel therapies. Driven by a commitment to patients with pediatric
onset life-altering diseases, the company's research and
development efforts leverage an internal genomics platform and an
ongoing collaboration with the Center for Applied Genomics (CAG) at
The Children's Hospital of Philadelphia (CHOP).
About Kyowa Hakko Kirin
Kyowa Hakko Kirin Co., Ltd. is a research-based life sciences
company, with special strengths in biotechnologies. In the core
therapeutic areas of oncology, nephrology and immunology / allergy,
Kyowa Hakko Kirin leverages leading-edge biotechnologies centered
on antibody technologies, to continually discover innovative new
drugs and to develop and market those drugs world-wide. In this
way, the company is working to realise its vision of becoming a
Japan-based global specialty
pharmaceutical company that contributes to the health and wellbeing
of people around the world. You can learn more about the
business at: www.kyowa-kirin.com.
Forward-looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the Company's
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use of
the terms and phrases such as "estimate," "project," "intend,"
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will," "will likely," "should," "could," "would," "may" or the
negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and
are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
CONTACT:
Aevi Genomic Medicine, Inc.
Brian Piper
Brian.Piper@aevigenomics.com
Westwicke Partners
Chris
Brinzey
+1-339-970-2843
Chris.brinzey@westwicke.com
MEDIA INQUIRIES:
FTI Consulting
Irma Gomez-Dib
+1-212-850-5761
+1-415-706-9155
irma.gomez-dib@fticonsulting.com
View original
content:http://www.prnewswire.com/news-releases/aevi-genomic-medicine-expands-collaboration-with-kyowa-hakko-kirin-300609506.html
SOURCE Aevi Genomic Medicine, Inc.